Stockscreener 앱 받기
2.07
3.94%
-0.085
시장 영업 전:
2.09
0.02
+0.97%
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Electra's IPO Break, Three CAR-T Deaths, and a Tariff Deadline Nobody Understands - finance.biggo.com
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Inc (NASDAQ: CABA) Share Price, CABA Stock News, CABA Share Price & Updates - kalkine.com.au
Cabaletta Bio Q2 2026 Earnings: Narrower-Than-Expected Loss Offers Modest ReliefSlow Growth Warning - careplusvn.com
Cabaletta Bio (NASDAQ: CABA) Raises $128.2M from Warrant Exercises by September 12, 2026 - Kalkine Media
Cabaletta Bio raises $128.2 million from warrant exercises ahead of expiration By Investing.com - Investing.com South Africa
Form 8K Cabaletta Bio Inc For: 14 September By Investing.com - Investing.com Australia
Cabaletta Bio raises $128.2 million from warrant exercises ahead of expiration - Investing.com
Cabaletta Bio warrant exercises bring $128.2M gross proceeds after June 2025 offering - TradingView
$2.50 share warrants bring new cash to Cabaletta Bio (CABA) - Stock Titan
Cabaletta Bio at cantorfitzgerald healthcare conference: safety and scale By Investing.com - Investing.com Canada
Cactus Cuts Q3 Pressure Control Outlook on Expected Double-Digit Revenue Decline - Minichart
Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely? - Moomoo
Cabaletta Bio Takes Autoimmune Cell Therapy Pitch to Investors - MyChesCo
CABA Stock Price and Chart — NASDAQ:CABA - TradingView
Cabaletta Bio Inc. (CABA) Key Financial Ratios – Valuation, Profitability & More - Value Research
TD Cowen Maintains Cabaletta Bio(CABA.US) With Buy Rating - Moomoo
CABA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $16 - GuruFocus
Cabaletta Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio Inc. (CABA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cabaletta Bio Inc (CABA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cabaletta (CABA) Earnings Reading: EPS Lands Above Forecast in the Current Update; Post-Report: Shares Finish 0.96% Down in the Available RecordProfit Growth Outlook - vinanet.vn
Blue Owl Capital Holdings LP Acquires New Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
WuXi Bio to offload chromatography unit; Cabaletta names another CDMO partner - Endpoints News
Cabaletta Targets 2027 BLA as Cell Therapy Trials Advance - MyChesCo
Cabaletta Bio (NASDAQ:CABA) Trading 10.3% HigherShould You Buy? - MarketBeat
Norges Bank Initiates New Position in Cabaletta Bio (CABA) With 8.7 Million Share Purchase - GuruFocus
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio (CABA) Rallies 5% as Biotech Sentiment ImprovesForce Index - vinanet.vn
HC Wainwright Raises Earnings Estimates for Cabaletta Bio - MarketBeat
Cabaletta Bio (CABA) Reports Promising Phase 1/2 Data Amid Unpro - GuruFocus
668,563 Shares in Cabaletta Bio, Inc. $CABA Bought by GSA Capital Partners LLP - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA) - The Globe and Mail
Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake - Stock Titan
CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00 - GuruFocus
Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Cabaletta Bio Releases Q2 2026 Financial Results - AlphaStreet
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress - Investing.com
Why is Cabaletta Bio stock sliding today? By Investing.com - Investing.com Australia
Why is Cabaletta Bio stock sliding today? - Investing.com
Cabaletta Bio Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Cabaletta Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cabaletta Bio (CABA) Q2 Earnings Beat Expectations; Market Focuses on Growth Potential Despite Losses - GuruFocus
Form 8K Cabaletta Bio Inc For: 13 August By Investing.com - Investing.com Nigeria
Cabaletta Bio Q2 net loss widens as R&D costs rise - TradingView
Cabaletta Bio, Inc. 2Q 2026: Net loss $(51.0)M, EPS $(0.34) — 10-Q Summary - TradingView
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio (NASDAQ: CABA) lifts cash to $225M while advancing CAR-T trials - Stock Titan
3.06%
2.55%
자본화:
|
볼륨(24시간):